Paclitaxel (taxol)
- PMID: 7885406
- DOI: 10.1056/NEJM199504133321507
Paclitaxel (taxol)
Erratum in
- N Engl J Med 1995 Jul 6;333(1):75
Similar articles
-
Neurotoxicity as a possible manifestation of paclitaxel hypersensitivity reactions.J Clin Oncol. 1994 May;12(5):1102-3. J Clin Oncol. 1994. PMID: 7909329 No abstract available.
-
Taxol: a promising new drug of the '90s.Oncol Nurs Forum. 1993 Nov-Dec;20(10):1483-9. Oncol Nurs Forum. 1993. PMID: 7904060 Review.
-
[Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].Harefuah. 1998 Apr 15;134(8):605-8, 671. Harefuah. 1998. PMID: 10911422 Clinical Trial. Hebrew.
-
What you need to know about Taxol.Am J Nurs. 1993 Dec;93(12):46-50. Am J Nurs. 1993. PMID: 7905707 No abstract available.
-
Paclitaxel: a new antineoplastic agent for refractory ovarian cancer.Clin Pharm. 1993 Jun;12(6):401-15. Clin Pharm. 1993. PMID: 7691462 Review.
Cited by
-
Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial.J Natl Cancer Cent. 2024 Apr 26;4(2):135-141. doi: 10.1016/j.jncc.2024.04.004. eCollection 2024 Jun. J Natl Cancer Cent. 2024. PMID: 39282588 Free PMC article.
-
Drug-eluting devices for lower limb peripheral arterial disease.EuroIntervention. 2024 Sep 16;20(18):e1136-e1153. doi: 10.4244/EIJ-D-23-01080. EuroIntervention. 2024. PMID: 39279515 Review.
-
Coronary Drug-Coated Balloons for De Novo and In-Stent Restenosis Indications.J Soc Cardiovasc Angiogr Interv. 2023 Mar 30;2(3):100625. doi: 10.1016/j.jscai.2023.100625. eCollection 2023 May-Jun. J Soc Cardiovasc Angiogr Interv. 2023. PMID: 39130710 Free PMC article. Review.
-
Revolutionizing cancer therapy using tetrahedral DNA nanostructures as intelligent drug delivery systems.Nanoscale Adv. 2024 May 28;6(15):3714-3732. doi: 10.1039/d4na00145a. eCollection 2024 Jul 23. Nanoscale Adv. 2024. PMID: 39050960 Free PMC article. Review.
-
Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis.Cell Rep. 2024 Jul 23;43(7):114431. doi: 10.1016/j.celrep.2024.114431. Epub 2024 Jul 4. Cell Rep. 2024. PMID: 38968071 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources